Core Viewpoint - Canaan Technology achieved significant growth in 2024, with a revenue of 1.38 billion yuan, marking a 32.1% year-on-year increase, and a return to profitability with a net profit of 36.27 million yuan, showcasing a strong recovery momentum in the pharmaceutical equipment industry [1][2]. Revenue Performance - The company reported a record high revenue of 1.38 billion yuan in 2024, driven by a dual strategy of "technology-driven + refined management" amidst global economic fluctuations and intensified industry competition [2]. - The main revenue contributors were oral solid dosage equipment and intelligent factory solutions, accounting for over 60% of total revenue, leveraging a "full-line delivery + process design" model [2]. R&D Investment - Canaan Technology's R&D investment reached 80.76 million yuan in 2024, with a total of 1,112 authorized patents, including 142 invention patents [3]. - The company has established partnerships with universities to enhance its R&D capabilities and has developed a clear organizational structure for research and development [3]. Service Capability Enhancement - The company is evolving from a pharmaceutical equipment supplier to a comprehensive solution provider, offering one-stop services including process development and project application [4]. - Canaan Technology serves over 50 countries and has established long-term partnerships with leading pharmaceutical companies, enhancing its market position and expanding its service capabilities [4]. Future Outlook - Looking ahead to 2025, the company aims to deepen its focus on the pharmaceutical equipment market and become a leading supplier of intelligent factory solutions, while also advancing in the health industry [5]. - The company plans to support innovation in biopharmaceutical equipment and continue optimizing its product offerings to enhance competitiveness and drive growth [5].